Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: A population-based study

Clinical Genitourinary Cancer

Volumn 13, Issue 3, 2015, Pages e123-e130

  Gandaglia, Giorgio ^a,b   Sun, Maxine ^a   Popa, Ioana ^a   Schiffmann, Jonas ^a   Trudeau, Vincent ^a   Shariat, Shahrokh F ^c   Trinh, Quoc Dien ^d   Graefen, Markus ^e   Widmer, Hugues ^a   Saad, Fred ^a   Briganti, Alberto ^b   Montorsi, Francesco ^b   Karakiewicz, Pierre I ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Baseline comorbidities; Cardiovascular diseases; Competing risks; Risk factors; Surveillance Epidemiology and End Results Medicare database

Indexed keywords

GONADORELIN AGONIST; ANTIANDROGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; METASTASIS; METASTATIC PROSTATE CANCER; ORCHIECTOMY; PROSTATE CANCER; SURVIVAL RATE; CORONARY ARTERY DISEASE; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CORONARY DISEASE; HUMANS; MALE; MORTALITY; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84929134001     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.12.003     Document Type: Article

References (29)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. E. Scosyrev, E.M. Messing, and S. Mohile et al. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality Cancer 118 2012 3062 3070
3. E. Scosyrev, G. Wu, and S. Mohile et al. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time Cancer 118 2012 5768 5776
4. A. Heidenreich, P.J. Bastian, and J. Bellmunt et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 65 2014 467 479
5. V. Pagliarulo, S. Bracarda, and M.A. Eisenberger et al. Contemporary role of androgen deprivation therapy for prostate cancer Eur Urol 61 2012 11 25
6. P.C. Albertsen, L. Klotz, and B. Tombal et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist Eur Urol 65 2014 565 573
7. G. Gandaglia, M. Sun, and J.C. Hu et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer Eur Urol 2014
8. G. Gandaglia, M. Sun, and I. Popa et al. The impact of the androgen deprivation therapy on the risk of coronary heart disease in patients with non-metastatic prostate cancer: a population-based study BJU Int 2014
9. V. Conteduca, G. Di Lorenzo, and A. Tartarone et al. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy Crit Rev Oncol Hematol 86 2013 42
10. M. Van Hemelrijck, H. Garmo, and L. Holmberg et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden J Clin Oncol 28 2010 3448
11. N.L. Keating, A.J. O'Malley, and S.J. Freedland et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 102 2010 39
12. M.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448
13. C.G. Jespersen, M. Norgaard, and M. Borre Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study Eur Urol 2013
14. C.S. Saigal, J.L. Gore, and T.L. Krupski et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer Cancer 110 2007 1493
15. J.L. Warren, C.N. Klabunde, and D. Schrag et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population Med Care 40 2002 IV
16. C.N. Klabunde, A.L. Potosky, and J.M. Legler et al. Development of a comorbidity index using physician claims data J Clin Epidemiol 53 2000 1258
17. G. Gandaglia, A. Becker, and Q.D. Trinh et al. Long-term survival in patients with germ cell testicular cancer: a population-based competing-risks regression analysis Eur J Surg Oncol 2013
18. H.G. Muller, and J.L. Wang Hazard rate estimation under random censoring with varying kernels and bandwidths Biometrics 50 1994 61
19. F. Abdollah, N. Suardi, and C. Cozzarini et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis Eur Urol 63 2013 998
20. National Vital Statistics Reports. Deaths: Preliminary Data for 2010. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60-04.pdf. Accessed July 7, 2012.
21. P.L. Nguyen, Y. Je, and F.A. Schutz et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials JAMA 306 2011 2359
22. R.P. Blankfield Androgen deprivation therapy for prostate cancer and cardiovascular death JAMA 307 2012 1252 author reply 1252
23. M.R. Smith, K.S. Finkelstein, and F.J. McGovern et al. Changes in body composition during androgen deprivation therapy for prostate cancer J Clin Endocrinol Metab 87 2002 599
24. H.F. Chen, E.B. Jeung, and M. Stephenson et al. Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro J Clin Endocrinol Metab 84 1999 743
25. F. Tanriverdi, D. Gonzalez-Martinez, and Y. Hu et al. GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males Clin Exp Immunol 142 2005 103
26. J.A. Efstathiou, K. Bae, and W.U. Shipley et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02 Eur Urol 54 2008 816
27. A.V. D'Amico, M.H. Chen, and A.A. Renshaw et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial JAMA 299 2008 289
28. A. Nanda, M.H. Chen, and M.H. Braccioforte et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction JAMA 302 2009 866
29. R.E. Langley, F.H. Cafferty, and A.A. Alhasso et al. Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09) Lancet Oncol 14 2013 306